ライフサイエンスコーパス: point-of-care

1 guide correct antibiotic prescription at the point of care.

2 be transformative if provided at or near the point of care.

3 bilirubin from several drops of blood at the point of care.

4 the performance of the Xpert Ebola assay at point of care.

5 s-sectional, professional impressions at the point of care.

6 cally evaluated its impact when delivered at point of care.

7 gment-elevation myocardial infarction at the point of care.

8 every vial from the point of release to the point of care.

9 ts promise for iron status assessment at the point-of-care.

10 safety control and environment monitoring at point-of-care.

11 form that could advance disease treatment at point-of-care.

12 entification and detection with naked eye in point-of-care.

13 with high sensitivity and specificity at the point-of-care.

14 ecentralized monitoring and design of future points of care.

15 Despite their intended use at the point of care, 26.3% of tests were evaluated in a labora

16 The use of BLAST at the point of care across 3 hospital ASPs resulted in greater

17 These exciting results open new horizons for point-of-care Alzheimer diagnosis and provide an attract

18 stics that could be performed at or near the point of care and by less-experienced operators, leading

19 lopment of simple and affordable devices for point of care and home-based diagnostics.

20 nable inexpensive molecular detection at the point-of-care and at home with minimal or no instrumenta

21 and miniaturized electrochemical systems for point-of-care and environmental diagnosis.

22 Such tools are expected to operate at the point-of-care and in resource-limited settings.

23 on-sensing platform is suitable for low-cost point-of-care and in-field testing applications.

24 step, making it highly convenient for use in point-of-care and resource-limited settings.

25 emical sensing is moving to the forefront of point-of-care and wearable molecular sensing technologie

26 Rapid point-of-care, antibody-based testing is not currently a

27 nts aged >/=45 y consulting with OA received point-of-care anxiety and depression screening by the GP

28 However, the mentioned techniques lack the point of care application as it demands huge capital cos

29 ysis capabilities to demonstrate a potential point-of-care application.

30 tocol for non-invasive diagnosis for various points of care application.

31 ibed here, allowing for robust platforms for point of care applications for cancer biomarkers in gene

32 marker detection are highly sought after for point of care applications.

33 Point-of-care applications and patients' real-time monit

34 me of 35min, featuring a great potential for point-of-care applications requiring continuous monitori

35 and microbial pathogens in a wide variety of point-of-care applications that impact human and animal

36 ender the material suitable for clinical and point-of-care applications where stability, throughput,

37 le preparation, making this translatable for point-of-care applications.

38 ng the assay platform to be more amenable to point-of-care applications.

39 a promising tool for clinical diagnosis and point-of-care applications.

40 rmat suitable for both laboratory and rapid, point-of-care applications.

41 le of high performance cardiac-bioassays for point-of-care applications.

42 t that could be implemented for clinical and point-of-care applications.

43 of C-reactive protein (CRP) measured with a point-of-care assay as a screening tool for active pulmo

44 trations were measured at study entry with a point-of-care assay using whole blood obtained by finger

45 let reactivity was assessed by the VerifyNow point-of-care assay; high on-treatment platelet reactivi

46 roach also has the potential to enable rapid point-of-care assays, as we demonstrate by performing NL

47 thine-dye clearance thereby allows sensitive point-of-care assessment of both organ functions simulta

48 work lays the foundation to develop a rapid, point-of-care AST and strengthen global antibiotic stewa

49 dge cluster randomized controlled trial of a point-of-care-based transfusion algorithm in consecutive

50 In this review I focus on point-of-care biomarkers that enhance the usefulness of

51 ng small molecules or whole cells for use in point of care biosensing.

52 via covalent linking) for demonstration as a point of care biosensor.

53 new possibilities for the implementation of point-of-care biosensors that enable fast, simple and ef

54 icenter prospective evaluation of the use of point-of-care BLAST by ASPs.

55 Tuberculosis is diagnosed at the point-of-care by the Ziehl-Neelsen sputum smear microsco

56 y, selectivity, robustness, and miniaturized point-of-care cancer diagnostics.

57 resource-limited settings in the near term, point of care CD4 cell counts might have a role in prior

58 ng compounds were randomly assigned (1:1) to point-of-care CD4 cell counts (366 compounds with 417 pa

59 Point-of-care CD4 cell counts can improve linkage to HIV

60 INTERPRETATION: Point-of-care CD4 cell counts in a resource-limited HBCT

61 The CIS included point-of-care CD4 testing at the time of diagnosis, acce

62 The CIS included point-of-care CD4+ testing at the time of an HIV-positiv

63 d by sedimentation technique], serology, and point-of-care circulating cathodic antigen [POC-CCA] uri

64 pe of neuraminidase assay may be useful in a point of care clinic to rapidly diagnose influenza infec

65 l-free biosensing techniques, especially for point-of-care clinical analysis where low analyte concen

66 ustrating the potential of the biosensor for point-of-care clinical applications.

67 ve diagnostic method for cystinuria, and for point-of-care clinical monitoring.

68 ss, the development and commercialization of point-of-care combination tests capable of detecting mar

69 alculated the sensitivity and specificity of point-of-care CRP and WHO symptom-based screening in ref

70 ed as the reference standard, sensitivity of point-of-care CRP and WHO symptom-based screening were s

71 Point-of-care CRP testing had 89% sensitivity (145 of 16

72 Compared with WHO symptom-based screening, point-of-care CRP testing had lower sensitivity (differe

73 -infected adults were enrolled and underwent point-of-care CRP testing.

74 HIV/AIDS programmes should consider point-of-care CRP-based tuberculosis screening to improv

75 ervices were funded publicly and free at the point of care delivery in 50 (42%), 48 (51%), and 46 (49

76 venue for the development of future on-site, point-of-care detection devices for medical and biologic

77 ed RT-RPA method shows promise for sensitive point-of-care detection of epidemic human norovirus, and

78 could become a rapid and useful tool for the point-of-care detection of EVs, with a total analysis ti

79 This automated system suitable for point-of-care detection rapidly identifies B. anthracis

80 r has shown the potential to graduate into a point-of-care detection tool for alpha-amylase.

81 jor public health threat that requires rapid point-of-care detection.

82 edures may make this test suitable for rapid point-of-care detection.

83 tection into a single cartridge suitable for point-of-care detection.

84 ble and real-time nucleic acid analysis as a Point of Care device.

85 sable, low-cost, simple, instrument-free and point-of-care device for the automated ELISA.

86 r platform, to be used on an electrochemical point-of-care device.

87 ex system, offering opportunities for future point of care devices and advancements in biomedical app

88 rgent need for the development of automatic, point-of-care devices for rapid diagnosis of the influen

89 So, sensitive and selective biosensors with point-of-care devices need to be explored to detect the

90 ices for in vivo sensing and, development of point-of-care devices to real-time diagnostics.

91 ental analysis to biomedical diagnostics and point-of-care devices.

92 ee, Deliverable to all end-users) status for point of care diagnosis in miniaturized settings.

93 fore, if GSS testing is being considered for point-of-care diagnosis of N. gonorrhoeae infection or N

94 s a potential cost-effective methodology for point-of-care diagnosis.

95 on, paving the way for single molecule-based point-of-care diagnosis.

96 ethod for quantifying total ANA for use as a point-of-care diagnostic aid.

97 Lateral flow immunoassays (LFIs) are point-of-care diagnostic assays that are designed for si

98 rofluidic paper analytical devices and other point-of-care diagnostic assays.

99 e development is reported of an ultra-rapid, point-of-care diagnostic device which harnesses surface

100 e implementation of amplification methods in point-of-care diagnostic devices and devices to be used

101 ators and non-invasive MRI measurements, and point-of-care diagnostic devices.

102 ow-cost, wearable and disposable devices for point-of-care diagnostic due to the widespread availabil

103 Colorimetric readouts are widely used in point-of-care diagnostic immunoassays to indicate either

104 A more accurate point-of-care diagnostic may be needed to support malari

105 or the detection of S. aureus as a potential point-of-care diagnostic platform in hospitals and for u

106 tant requirement toward a nucleic-acid-based point-of-care diagnostic system.

107 ne-based chloride sensor, paving the way for point-of-care diagnostic systems for CF.

108 tions and would greatly benefit from a rapid point-of-care diagnostic test.

109 Affordable, rapid point-of-care diagnostic tests (as have been developed f

110 progress and challenges in developing rapid point-of-care diagnostic tests and vaccines to prevent d

111 from clinics to laboratories, and the use of point-of-care diagnostic tests, will also be important f

112 noassay (LFA) is one of the most widely used point-of-care diagnostic tests; however, LFAs generally

113 fever, this assay could be used as a rapid, point-of-care diagnostic to determine the cause of a fev

114 This aptasensor holds great promise as a new point-of-care diagnostic tool for analyzing glycan expre

115 mance make our biosensor an ideal choice for point of care diagnostics and personal healthcare system

116 ials for neuroscience diagnostics, clinical, point-of-care diagnostics and medical industries are als

117 search efforts, including the development of point-of-care diagnostics and microneedle patches, will

118 ion method that has shown many advantages in point-of-care diagnostics and personalized medicine.

119 gies to monitor ZIKV progression, with rapid point-of-care diagnostics as the ultimate aim.

120 ors have recently been advanced for portable point-of-care diagnostics by integrating lab-on-a-chip t

121 llance efforts employing rapid and effective point-of-care diagnostics designed for environments that

122 cation in clinical diagnosis and can improve point-of-care diagnostics of dengue infection.

123 cations in a wide range of fields, including point-of-care diagnostics or cellular in vivo biosensing

124 developing low-cost portable biosensors for point-of-care diagnostics using traditional optical, mas

125 biosensor will be useful in high-throughput point-of-care diagnostics with its minimizing size, ligh

126 The increasing needs of point-of-care diagnostics, quarantine of epidemic pathog

127 towards validating this strategy for rapid, point-of-care diagnostics.

128 MRX and provides an alternative platform for point-of-care diagnostics.

129 y has the potential to revolutionize medical Point-of-Care diagnostics.

130 of applications in point-of-use testing and point-of-care diagnostics.

131 is a promising new biosensing technique for point-of-care diagnostics.

132 ive means, which is a critical attribute for point-of-care diagnostics.

133 ployment of QCL-based devices in routine and point-of-care diagnostics.

134 patients with disseminated tuberculosis, and point-of-care dilated binocular indirect ophthalmoscopy

135 orescent and colorimetric assays that enable point-of-care DNA and RNA detection has been a topic of

136 this work to address the lack of a reliable point-of-care drug monitoring system in the market.

137 drive its development ahead of the outbreak, point-of-care Ebola tests supporting a less costly and m

138 rties of graphene for in vitro, in vivo, and point-of-care electrochemical biosensing.

139 h which 9 quantitative (laboratory-based and point-of-care) FITs detected advanced neoplasms (AN) in

140 that could be implemented in-line and at the point-of-care for real-time decision-making about the qu

141 ng the valve fairly easy to incorporate into point-of-care format.

142 e rapid detection of nucleic acids in simple point-of-care formats with high sensitivity and specific

143 re, human immunodeficiency virus status, and point-of-care glucose and lipid levels.

144 nonobstetric adult inpatients who underwent point-of-care glucose testing.

145 Urethral swabs are the samples of choice for point-of-care Gram stain testing to diagnose Neisseria g

146 Of 371 participants in the point-of-care group, 215 (58%) had linked to care within

147 to provide clinicians with more interactive, point-of-care guidance with ASCO's abiding commitment to

148 itals, a transfusion algorithm incorporating point-of-care hemostatic testing was sequentially implem

149 Point-of-care hepatitis C virus (HCV) RNA testing offers

150 The One4All strategy incorporated rapid, point-of-care HIV screening and CD4 counts, and in-paral

151 filariae in peripheral blood, enables rapid, point-of-care identification of persons at risk for seri

152 ology continues to be considered an advanced point-of-care imaging modality and should be used select

153 ker that will be exploited in a quantitative point-of-care immunoassay for determination of L. loa mf

154 performance, and suitability for use at the point-of-care in resource-limited settings.

155 ns and used for rapid multianalyte tests for point-of-care in vitro diagnostics, food analysis, biosa

156 ts should provide clinicians with the timely point-of-care information required to adjust dosages and

157 review was then compared with institutional point-of-care interpretation.

158 ing interpretation guidance available at the point of care is recommended.

159 pathogens (i.e. bacteria and viruses) at the point-of-care is also shown.

160 Technologic advances are leading to point-of-care kits that incorporate nucleic acid-based a

161 oke unit) equipped with an imaging system, a point-of-care laboratory, a telemedicine connection to t

162 ethods have a potential to be used for rapid point-of-care measurements of AHB that could enhance pop

163 rations during the first 10 days of therapy (point-of-care measurements; non-inferiority was deemed a

164 h should address the growing needs for rapid point-of-care medical diagnosis in ICU.

165 effective tool for clinical application and point-of-care medical diagnostics.

166 rd the potential of UV Raman spectroscopy as point-of-care method for therapeutic drug monitoring (TD

167 We therefore developed a point-of-care mobile phone-based platform that can quick

168 Accurate, easy to use, and inexpensive point of care molecular diagnostic tests are urgently ne

169 ing tool to create antigens for research and point-of-care monitoring of anti-DNA antibodies.

170 kers associated with heart muscle damage and point-of-care monitoring of both these two biomarkers ha

171 re suitable for the development of multiplex point-of-care neglected diseases sensing applications.

172 We compared two rapid, point-of care nucleic acid amplification tests for detec

173 Here we report on the development of a point-of-care nucleic acid lateral flow test for the dir

174 aptasensor has the potential to be used for point-of-care one-step detection of norovirus in clinica

175 ectroscopy system can potentially enable new point-of-care opportunities, such as cancer screening.

176 Current analytical methods, either point-of-care or centralized detection, are not able to

177 d and highlight the potential for use at the point-of-care or for patient self-testing.

178 expensive and bulky, thus cannot be used at point-of-care or in the field.

179 d for integration into clinical practice for point-of-care or molecular detection of bacterial DNA fr

180 and sensitive nucleic acid detection may aid point-of-care pathogen detection, genotyping, and diseas

181 signed for inclusion in either an integrated point-of-care platform or a high throughput automated ce

182 c acid aptamer with an antibody for use as a point-of-care platform which can detect particular strai

183 hods which have restrictions when applied to point of care (POC) applications.

184 in a traditional clinical setting and in the point of care (POC) arena.

185 to develop a multiplexed rapid lab-on-a-chip point of care (POC) assay for the serologic diagnosis of

186 tion devices which hold immense potential as point of care (POC) tools.

187 logical protocol suitable for further use as point-of-care (POC) analysis and ii) two dedicated image

188 leic acid-based molecular diagnostics at the point-of-care (POC) and in resource-limited settings is

189 ology for cytochrome c (cyt c) detection, at point-of-care (POC) application.

190 The feasibility of the sensor for point-of-care (POC) applications was further demonstrate

191 There is a global need for HIV viral load point-of-care (PoC) assays to monitor patients receiving

192 To detect biomarkers more conveniently, point-of-care (PoC) biosensors, which are easy to use an

193 on arm of the study ("rapid arm") received a point-of-care (POC) CD4 count if needed; those who were

194 ogy that intended to develop next generation point-of-care (POC) detection system.

195 hallenge is the lack of a rapid and accurate point-of-care (PoC) device that can perform these measur

196 gy provide an elegant solution for low-cost, point-of-care (POC) devices and lab-on-a-chip (LOC) appl

197 Quantitative point-of-care (POC) devices are the next generation for

198 idered as a promising opportunity to develop Point-of-Care (POC) devices for an efficient, simple and

199 Microfluidic point-of-care (POC) devices have been designed to addres

200 icrofluidic approach has great potential for point-of-care (POC) diagnosis of multiple infectious dis

201 Point-of-care (POC) diagnostic devices are integral in t

202 lfill the requirement for the development of point-of-care (POC) diagnostic technologies for human im

203 Point-of-care (POC) diagnostic testing platforms are a g

204 obile, and inexpensive, making them valuable point-of-care (POC) diagnostic tools.

205 Point-of-care (POC) diagnostics are one of the quick and

206 For the developing world, point-of-care (POC) diagnostics design must account for

207 flow assays (LFAs) are highly attractive for point-of-care (POC) diagnostics for infectious disease,

208 RATIONALE: Point-of-care (POC) diagnostics have the potential to re

209 The detection of nucleic acid biomarkers for point-of-care (POC) diagnostics is currently limited by

210 Point-of-care (POC) diagnostics provide rapid actionable

211 , along with developments in cloud-connected point-of-care (POC) diagnostics technologies are pushing

212 ential to be miniaturized for application in point-of-care (POC) diagnostics.

213 The established point-of-care (POC) FO-SPR bioassay was also used to mea

214 itive, and selective sensor to detect EVD at point-of-care (POC) is certainly worth exploring to esta

215 nsor chip to quantify salivary cortisol at a point-of-care (POC) level.

216 icrobiology convened a colloquium to examine point-of-care (POC) microbiology testing and to evaluate

217 Compared with other point-of-care (POC) nucleic acid tests (NAT), MTNT could

218 M range), making it suitable for a practical point-of-care (POC) platform for low target count clinic

219 We have developed a point-of-care (POC) quantitative immunoassay for HbS to

220 iagnosis of bladder cancer in clinics and at point-of-care (POC) settings.

221 al detection is particularly well suited for point-of-care (POC) specific protein detection, being of

222 Point-of-care (POC) technologies for HIV diagnosis in in

223 We examined the impact of a hypothetical point-of-care (POC) test reporting antibiotic susceptibi

224 cence microscopy has various applications in point-of-care (POC) testing and diagnostics, ranging fro

225 easy to use, our microdevice is suitable for point-of-care (POC) testing with high simplicity, provid

226 current methods are too complex or bulky for point-of-care (POC) use.

227 aches to TB diagnosis have been attempted at Point-of-Care (PoC), exploiting a large variation of tec

228 The implementation of biosensors at the point-of-care (POC), such as at primary clinics or the b

229 care in resource-constrained settings at the point-of-care (POC), where reliable electricity and refr

230 cleic acid testing that is deployable at the point-of-care (POC).

231 ality in hand-held devices to be used at the point-of-care (POC).

232 -based immunoassays are currently needed for point-of-care quantification of Loa loa microfilariae (m

233 To improve point-of-care quantification using microchip capillary e

234 Effective viral load monitoring and point-of-care resistance tests could help to mitigate th

235 Nomograms were developed to facilitate point-of-care risk assessment.

236 ally provides a rapid, easy to use means for point-of-care screening for iron deficiency in resource-

237 iomarkers may have potential as quantitative point-of-care screening tools to alert physicians to the

238 mbination of synthetic biology and scalable, point-of-care sensing has potential to provide low-cost,

239 We report a disposable point-of-care sensing platform specific to salivary cort

240 Here we describe the development of a point-of-care sensor for the detection of folic acid pro

241 -I (cTnI) and cardiac-Troponin-T (cTnT) in a point-of-care sensor format.

242 sensing system towards realizing a reusable, point-of-care sensor that snugly fits around a smartphon

243 ltiple assay to identify AD progression in a point of care setting.

244 n assisting screening of TBI patients in the point-of-care setting.

245 oantibodies are challenging to transfer to a point-of-care setting.

246 amplification-based detection assays towards point-of-care settings where they are needed most.

247 approach could enable testing for XDR-TB in point-of-care settings, potentially identifying highly d

248 roteins in small sample volumes (<25 muL) in point-of-care settings.

249 ude of autoimmune and infectious diseases in point-of-care settings.

250 titative immunoassays in both laboratory and point-of-care settings.

251 e investigate if it is possible to develop a point-of-care susceptibility test for urinary tract infe

252 This phone-based point-of-care system provides the potentially life-savin

253 the Ziplex System, which has potential as a point-of-care system.

254 Simple and disposable point of care systems are usually the best solution for

255 tic fibrosis (CF), but the implementation of point-of-care systems for diagnosis is hindered by the p

256 y of this method for clinical application in point-of-care technology is evaluated using Ebola glycop

257 nd portable solution is in highly demand for point of care test.

258 trip system for measuring GA is suitable for point-of-care test (POCT) applications.

259 hat converts the sandwich immunoassay into a point-of-care test (POCT).

260 The OraQuick Advance Rapid HIV-1/2 Test is a point-of-care test capable of detecting human immunodefi

261 nalytically at concentrations suitable for a point-of-care test device.

262 re Regression (PLS-R) have been applied as a point-of-care test for identifying malaria parasites, bl

263 Test (ReEBOV RDT) was expedited to provide a point-of-care test for suspected EVD cases.

264 Point-of-care test participants received additional coun

265 an 30 min, which allows the development of a point-of-care test that can guide correct treatment of u

266 is B surface antigen (HBsAg) screening via a point-of-care test.

267 nect the immunosensor for regular checkup in point of care testing with the ability to transfer data

268 Point-of-care testing (POCT) among HIV-exposed infants m

269 velopment of smartphone-based biosensors for point-of-care testing (POCT) applications allows realizi

270 D has great potential for the development of point-of-care testing (POCT) devices that can be applied

271 Rapid point-of-care testing (POCT) for respiratory viruses mig

272 od was proved to be a promising platform for point-of-care testing for neurotransmitters.

273 Quantitative microfluidic point-of-care testing has been translated into clinical

274 could facilitate control, however widespread point-of-care testing is infrequently done due to the la

275 ry has advanced due to the implementation of point-of-care testing, which is often performed within m

276 ould be applied in conventional microfluidic point-of-care testing.

277 to operate and is a promising technology for point-of-care testing.

278 ed with increasing access to microbiological point-of-care testing.

279 rted adult-specific data, and none evaluated point-of-care testing.

280 d photostability are needed, for example, in point-of-care testing.

281 cteremia using a system that is suitable for point-of-care testing.

282 We developed a lung function monitoring point-of-care-testing device (LFM-POCT) consisting of mo

283 ported as phenotypically normal with current point of care tests.

284 cal signs and have not made use of available point-of-care tests (POCTs) that can help to identify ch

285 portance of detecting ions and molecules for point-of-care tests has driven the search for more sensi

286 Use of combined point-of-care tests increased case finding, with a short

287 strategies for case management, focusing on point-of-care tests that hold considerable potential for

288 e underway to develop inexpensive, reliable, point-of-care tests to diagnose infection.

289 ted by the development of rational sampling, point-of-care tests, and extended automation as well as

290 g and categorizing disease phenotypes at the point of care, thus reducing unnecessary therapy and cos

291 , and robust measurement is available at the point-of-care to assist clinicians in detecting oxidativ

292 ulture and therefore, is not compatible with point-of-care treatment.

293 ods; and v) comparison with state-of-the-art point-of-care tuberculosis biosensors.

294 tings and by different users, proficiency in point-of-care ultrasound requires dedicated training in

295 hieve rapid and low-cost WBC analysis at the point-of-care under resource limited conditions.

296 Thus, the point of care use of ultrasound can reduce central venou

297 This technology is suitable for point-of-care use in both resource-rich and resource-lim

298 s resistance to the drug isoniazid (INH) for point-of-care use.

299 resented here has potential for use in rapid point-of-care UTI screening.

300 cardiography can be readily performed at the point of care with reasonable image quality.